LYEL Cash-Secured Put Strategy
LYEL (Lyell Immunopharma, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company’s lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; and CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
LYEL (Lyell Immunopharma, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $270.9M, a beta of -0.09 versus the broader market, a 52-week range of 8.632-45, average daily share volume of 128K, a public-listing history dating back to 2021, approximately 161 full-time employees. These structural characteristics shape how LYEL stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of -0.09 indicates LYEL has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a cash-secured put on LYEL?
A cash-secured put sells an out-of-the-money put while holding cash equal to the strike-times-100 obligation, keeping the premium when the underlying stays above the strike.
Current LYEL snapshot
As of June 29, 2026, spot at $12.75, ATM IV 340.80%, IV rank 77.71%, expected move 97.70%. The cash-secured put on LYEL below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 18-day expiry.
Why this cash-secured put structure on LYEL specifically: LYEL IV at 340.80% is rich versus its 1-year range, which favors premium-selling structures like a LYEL cash-secured put, with a market-implied 1-standard-deviation move of approximately 97.70% (roughly $12.46 on the underlying). The 18-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated LYEL expiries trade a higher absolute premium for lower per-day decay. Position sizing on LYEL should anchor to the underlying notional of $12.75 per share and to the trader's directional view on LYEL stock.
LYEL cash-secured put setup
The LYEL cash-secured put below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With LYEL near $12.75, the first option leg uses a $12.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed LYEL chain at a 18-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 LYEL shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Sell 1 | Put | $12.00 | $2.65 |
LYEL cash-secured put risk and reward
- Net Premium / Debit
- +$265.00
- Max Profit (per contract)
- $265.00
- Max Loss (per contract)
- -$934.00
- Breakeven(s)
- $9.35
- Risk / Reward Ratio
- 0.284
Max profit equals premium times 100; max loss equals strike minus premium times 100 (at zero, assuming assignment). Breakeven is strike minus premium.
LYEL cash-secured put payoff curve
Modeled P&L at expiration across a range of underlying prices for the cash-secured put on LYEL. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -99.9% | -$934.00 |
| $2.83 | -77.8% | -$652.20 |
| $5.65 | -55.7% | -$370.40 |
| $8.46 | -33.6% | -$88.60 |
| $11.28 | -11.5% | +$193.20 |
| $14.10 | +10.6% | +$265.00 |
| $16.92 | +32.7% | +$265.00 |
| $19.74 | +54.8% | +$265.00 |
| $22.55 | +76.9% | +$265.00 |
| $25.37 | +99.0% | +$265.00 |
When traders use cash-secured put on LYEL
Cash-secured puts on LYEL earn premium while a trader waits to acquire LYEL stock at a target strike below the current quote; most attractive when IV is rich and the trader is comfortable owning LYEL.
LYEL thesis for this cash-secured put
The market-implied 1-standard-deviation range for LYEL extends from approximately $0.29 on the downside to $25.21 on the upside. A LYEL cash-secured put lets a trader earn premium while waiting to acquire LYEL at the strike price; the strategy is most attractive when the trader is comfortable holding the underlying at that level and IV is rich enough to compensate for the assignment risk. Current LYEL IV rank near 77.71% sits in the upper third of its 1-year distribution, which historically reverts; this raises the bar for premium-buying structures and lowers it for premium-selling structures on LYEL at 340.80%. As a Healthcare name, LYEL options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to LYEL-specific events.
LYEL cash-secured put positions are structurally neutral to slightly bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. LYEL positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move LYEL alongside the broader basket even when LYEL-specific fundamentals are unchanged. Short-premium structures like a cash-secured put on LYEL carry tail risk when realized volatility exceeds the implied move; review historical LYEL earnings reactions and macro stress periods before sizing. Always rebuild the position from current LYEL chain quotes before placing a trade.
Frequently asked questions
- What is a cash-secured put on LYEL?
- A cash-secured put on LYEL is the cash-secured put strategy applied to LYEL (stock). The strategy is structurally neutral to slightly bullish: A cash-secured put sells an out-of-the-money put while holding cash equal to the strike-times-100 obligation, keeping the premium when the underlying stays above the strike. With LYEL stock trading near $12.75, the strikes shown on this page are snapped to the nearest listed LYEL chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are LYEL cash-secured put max profit and max loss calculated?
- Max profit equals premium times 100; max loss equals strike minus premium times 100 (at zero, assuming assignment). Breakeven is strike minus premium. For the LYEL cash-secured put priced from the end-of-day chain at a 30-day expiry (ATM IV 340.80%), the computed maximum profit is $265.00 per contract and the computed maximum loss is -$934.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a LYEL cash-secured put?
- The breakeven for the LYEL cash-secured put priced on this page is roughly $9.35 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current LYEL market-implied 1-standard-deviation expected move is approximately 97.70%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a cash-secured put on LYEL?
- Cash-secured puts on LYEL earn premium while a trader waits to acquire LYEL stock at a target strike below the current quote; most attractive when IV is rich and the trader is comfortable owning LYEL.
- How does current LYEL implied volatility affect this cash-secured put?
- LYEL ATM IV is at 340.80% with IV rank near 77.71%, which is elevated relative to its 1-year range. Premium-selling structures (covered call, cash-secured put, iron condor) generally look more attractive when IV rank is high; premium-buying structures (long call, long put, debit spreads) are more expensive in that regime.